Centessa Pharmaceuticals plc
CNTA
$39.59
-$0.02-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.00M | 15.00M | 15.00M | 15.00M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.00M | 15.00M | 15.00M | 15.00M | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 15.00M | 15.00M | 15.00M | 15.00M | -- |
| SG&A Expenses | 50.47M | 50.18M | 50.45M | 49.71M | 50.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 222.69M | 228.80M | 221.42M | 210.74M | 201.06M |
| Operating Income | -207.69M | -213.80M | -206.42M | -195.74M | -201.06M |
| Income Before Tax | -195.71M | -239.31M | -226.54M | -220.09M | -232.91M |
| Income Tax Expenses | 1.82M | 3.39M | 3.83M | 3.76M | 2.84M |
| Earnings from Continuing Operations | -197.53 | -242.70 | -230.37 | -223.85 | -235.76 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -197.53M | -242.70M | -230.37M | -223.85M | -235.76M |
| EBIT | -207.69M | -213.80M | -206.42M | -195.74M | -201.06M |
| EBITDA | -206.93M | -213.03M | -205.65M | -194.96M | -200.25M |
| EPS Basic | -1.45 | -1.83 | -1.78 | -1.81 | -1.99 |
| Normalized Basic EPS | -0.90 | -0.96 | -0.94 | -0.95 | -1.06 |
| EPS Diluted | -1.45 | -1.83 | -1.78 | -1.81 | -1.99 |
| Normalized Diluted EPS | -0.90 | -0.96 | -0.94 | -0.95 | -1.06 |
| Average Basic Shares Outstanding | 542.86M | 532.92M | 515.02M | 490.83M | 457.68M |
| Average Diluted Shares Outstanding | 542.86M | 532.92M | 515.02M | 490.83M | 457.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |